StockData
Camp4 Therapeutics Corp logo

Camp4 Therapeutics Corp (CAMP) stock

CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$4.00+0.14 (+3.63%)

Close on Nov 17, 2026Market cap $251.01MP/E –Yield 0.00%

Camp4 Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Camp4 Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$52.88M. For fiscal 2025 it was -$52.56M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$52.56M–
FY2024Dec 31, 2024-$53.09M–
FY2023Dec 31, 2023-$51.88M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$13.38M–
Q1 FY2026Mar 31, 2026-$13.07M–
Q4 FY2025Dec 31, 2025-$12.78M–
Q3 FY2025Sep 30, 2025-$13.65M–
Q2 FY2025Jun 30, 2025-$13.03M–
Q1 FY2025Mar 31, 2025-$13.10M–
Q4 FY2024Dec 31, 2024-$14.03M–
Q3 FY2024Sep 30, 2024-$13.52M–
Q2 FY2024Jun 30, 2024-$12.66M–
Q1 FY2024Mar 31, 2024-$12.88M–
Q4 FY2023Dec 31, 2023-$13.48M–
Q3 FY2023Sep 30, 2023-$12.34M–

More Camp4 Therapeutics figures

See a number that looks wrong?